<?xml version="1.0" encoding="UTF-8" standalone="no"?><document setID="cbc31ab1-a80f-4b50-a3b1-39910b0fb609"><labelDrug name="TYVASO"><Normalization><mmtx cui="C2718336" preferredWord="Tyvaso" semType="phsu, orch"/></Normalization></labelDrug><generic name="treprostinil"/><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.1" text="TYVASO (treprostinil) inhalant" type="negative"><entity charOffset="8:20" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.1.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="0:6" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.1.e.1" text="tyvaso" type="Biomedical_Entity"><Normalization><mmtx cui="C2718336" phraseText="TYVASO" preferredWord="Tyvaso" semType="phsu, orch"/><RxNorm RxCui="857796"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.1.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.1.e.0"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.9" text="Therapy should begin with 3 breaths of Tyvaso (18 mcg of treprostinil), per treatment session, 4 times daily. " type="negative"><entity charOffset="57:69" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.9.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(18 mcg of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="39:45" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.9.e.1" text="tyvaso" type="Biomedical_Entity"><Normalization><mmtx cui="C2718336" phraseText="begin with 3 breaths of Tyvaso" preferredWord="Tyvaso" semType="phsu, orch"/><RxNorm RxCui="857796"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.9.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.9.e.0"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.29" text="Treprostinil is a pulmonary and systemic vasodilator. " type="negative"><entity charOffset="41:52" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.29.e.0" text="vasodilator" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="systemic vasodilator." preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="0:12" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.29.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="Treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.29.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.29.e.0"/></sentence><sentence biomedicalEntities="2" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34" lineNumber="53" text="Since Tyvaso inhibits platelet aggregation, there may be an increased risk of bleeding, particularly among patients receiving anticoagulant therapy." type="regular"><entity charOffset="126:147" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.0" text="anticoagulant therapy" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="anticoagulant therapy." preferredWord="Anticoagulants" semType="phsu"/><mmtx cui="C3536711" phraseText="anticoagulant therapy." preferredWord="Anti-coagulant [EPC]" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><entity charOffset="6:12" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.1" text="Tyvaso" type="Drug"><Normalization><mmtx cui="C2718336" phraseText="Tyvaso" preferredWord="Tyvaso" semType="phsu, orch"/><RxNorm RxCui="857796"/></Normalization></entity><entity charOffset="78:86" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.2" text="bleeding" type="Specific_Interaction"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.2"><relations><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.0" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.34.e.2" type="Specific_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36" lineNumber="57" text="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor (e.g., gemfibrozil) may increase exposure (both Cmax and AUC) to treprostinil. " type="regular"><entity charOffset="23:65" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0" text="cytochrome P450 (CYP) 2C8 enzyme inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0014432" phraseText="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor" preferredWord="Enzyme Inhibitors" semType="phsu"/><mmtx cui="C0919438" phraseText="Co-administration of a cytochrome P450 (CYP) 2C8 enzyme inhibitor" preferredWord="Enzyme Inhibitor Drugs" semType="phsu"/><RxNorm RxCui="3065"/></Normalization></entity><entity charOffset="73:84" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.1" text="gemfibrozil" type="Drug"><Normalization><mmtx cui="C0017245" phraseText="gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><RxNorm RxCui="4719"/></Normalization></entity><entity charOffset="131:143" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.3" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="AUC) to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="90:107|114:118" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.4" text="increase exposure Cmax" type="Increase_Interaction"/><entity charOffset="90:107|123:126" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.6" text="increase exposure AUC" type="Increase_Interaction"/><drugClassMembership drug="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.1" drugClass="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.ddi.2"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.3" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.36.e.4" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37" lineNumber="57" text="Co-administration of a CYP2C8 enzyme inducer (e.g., rifampin) may decrease exposure to treprostinil. " type="regular"><entity charOffset="23:44" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.0" text="CYP2C8 enzyme inducer" type="Drug_Class"><Normalization><RxNorm RxCui="687277"/></Normalization></entity><entity charOffset="52:60" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="66:83" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.3" text="decrease exposure" type="Decrease_Interaction"/><entity charOffset="87:99" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.5" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="exposure to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><drugClassMembership drug="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.1" drugClass="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.0"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.3"><relations><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.5"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.5" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.37.e.3" type="Decrease_Interaction"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.40" text="Pharmacokinetic/pharmacodynamic interaction studies have not been conducted with inhaled treprostinil (Tyvaso); " type="negative"><entity charOffset="89:101" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.40.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="conducted with inhaled treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="103:109" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.40.e.1" text="tyvaso" type="Biomedical_Entity"><Normalization><mmtx cui="C2718336" phraseText="(Tyvaso" preferredWord="Tyvaso" semType="phsu, orch"/><RxNorm RxCui="857796"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.40.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.40.e.1"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41" text="however, some of such studies have been conducted with orally (treprostinil diolamine) and subcutaneously administered treprostinil (Remodulin )." type="negative"><entity charOffset="76:85" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.0" text="diolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="10208"/></Normalization></entity><entity charOffset="63:75" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="119:131" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.2" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="subcutaneously administered treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="133:142" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.3" text="remodulin" type="Biomedical_Entity"><Normalization><mmtx cui="C1101501" phraseText="(Remodulin" preferredWord="Remodulin" semType="phsu, lipd"/><RxNorm RxCui="323640"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.2"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.41.e.3"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.43" text="7.1 Antihypertensive Agents or Other Vasodilators" type="negative"><entity charOffset="4:27" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.43.e.0" text="antihypertensive agents" type="Biomedical_Entity"><Normalization><mmtx cui="C0003364" phraseText="7.1 Antihypertensive Agents" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="37:49" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.43.e.1" text="vasodilators" type="Biomedical_Entity"><Normalization><mmtx cui="C0042402" phraseText="Other Vasodilators" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.43.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.43.e.1"/></sentence><sentence biomedicalEntities="4" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44" lineNumber="67" text="Concomitant administration of Tyvaso with diuretics, antihypertensive agents or other vasodilators may increase the risk of symptomatic hypotension." type="regular"><entity charOffset="42:51" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.0" text="diuretics" type="Drug_Class"><Normalization><mmtx cui="C0012798" phraseText="with diuretics," preferredWord="Diuretics" semType="phsu"/><RxNorm RxCui="3567"/></Normalization></entity><entity charOffset="30:36" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.1" text="Tyvaso" type="Drug"><Normalization><mmtx cui="C2718336" phraseText="Concomitant administration of Tyvaso" preferredWord="Tyvaso" semType="phsu, orch"/><RxNorm RxCui="857796"/></Normalization></entity><entity charOffset="53:76" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.2" text="antihypertensive agents" type="Drug_Class"><Normalization><mmtx cui="C0003364" phraseText="antihypertensive agents" preferredWord="Antihypertensive Agents" semType="phsu"/><RxNorm RxCui="968"/></Normalization></entity><entity charOffset="86:98" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.3" text="vasodilators" type="Drug_Class"><Normalization><mmtx cui="C0042402" phraseText="other vasodilators" preferredWord="Vasodilator Agents" semType="phsu"/><RxNorm RxCui="11146"/></Normalization></entity><entity charOffset="124:147" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.4" text="symptomatic hypotension" type="Specific_Interaction"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.3"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.0"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.1"/></relation><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.2"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.3" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.0" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.4" type="Specific_Interaction"/><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.2" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.4" type="Specific_Interaction"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.44.e.2"/></sentence><sentence biomedicalEntities="2" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46" lineNumber="71" text="Since treprostinil inhibits platelet aggregation, there may be an increased risk of bleeding, particularly among patients receiving anticoagulants." type="regular"><entity charOffset="6:18" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.0" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="84:92" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.1" text="bleeding" type="Specific_Interaction"/><entity charOffset="132:146" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.3" text="anticoagulants" type="Drug_Class"><Normalization><mmtx cui="C0003280" phraseText="anticoagulants." preferredWord="Anticoagulants" semType="phsu"/><RxNorm RxCui="923"/></Normalization></entity><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.1"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.0"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.3" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.46.e.1" type="Specific_Interaction"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49" text="In a human pharmacokinetic study conducted with bosentan (250 mg/day) and an oral formulation of treprostinil (treprostinil diolamine), no pharmacokinetic interactions between treprostinil and bosentan were observed." type="negative"><entity charOffset="48:56" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.0" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="conducted with bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><entity charOffset="176:188" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="no pharmacokinetic interactions between treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="111:123" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.2" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="124:133" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3" text="diolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="10208"/></Normalization></entity><entity charOffset="97:109" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.4" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="an oral formulation of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="193:201" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.5" text="bosentan" type="Biomedical_Entity"><Normalization><mmtx cui="C0252643" phraseText="bosentan" preferredWord="bosentan" semType="phsu, orch"/><RxNorm RxCui="75207"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.2"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.4"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.5"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.5"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.4" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.5"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.4" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.49.e.5"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51" text="In a human pharmacokinetic study conducted with sildenafil (60 mg/day) and an oral formulation of treprostinil (treprostinil diolamine), no pharmacokinetic interactions between treprostinil and sildenafil were observed." type="negative"><entity charOffset="177:189" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="no pharmacokinetic interactions between treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="112:124" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="(treprostinil diolamine" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="125:134" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2" text="diolamine" type="Biomedical_Entity"><Normalization><mmtx cui="C0057919" phraseText="(treprostinil diolamine" preferredWord="diethanolamine" semType="phsu, orch"/><RxNorm RxCui="10208"/></Normalization></entity><entity charOffset="48:58" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.3" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="conducted with sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><entity charOffset="194:204" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.4" text="sildenafil" type="Biomedical_Entity"><Normalization><mmtx cui="C0529793" phraseText="sildenafil" preferredWord="sildenafil" semType="phsu, orch"/><RxNorm RxCui="136411"/></Normalization></entity><entity charOffset="98:110" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.5" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="an oral formulation of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.4"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.4"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.4"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.5" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.2"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.5"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.5" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.51.e.4"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.53" text="In vitro studies of human hepatic microsomes showed that treprostinil does not inhibit cytochrome P450 (CYP) isoenzymes CYP1A2, CYP2A6, CYP2C8, CYP2C9, CYP2C19, CYP2D6, CYP2E1 and CYP3A. " type="negative"><entity charOffset="57:69" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.53.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="that treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="109:119" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.53.e.1" text="isoenzymes" type="Biomedical_Entity"><Normalization><mmtx cui="C1442929" phraseText="cytochrome P450 (CYP) isoenzymes CYP1A2," preferredWord="Clinically relevant isoenzyme" semType="phsu, aapp, enzy"/><RxNorm RxCui="6021"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.53.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.53.e.1"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.54" text="Additionally, treprostinil does not induce cytochrome P450 isoenzymes CYP1A2, CYP2B6, CYP2C9, CYP2C19, and CYP3A." type="negative"><entity charOffset="14:26" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.54.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="59:69" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.54.e.1" text="isoenzymes" type="Biomedical_Entity"><Normalization><mmtx cui="C1442929" phraseText="cytochrome P450 isoenzymes CYP1A2," preferredWord="Clinically relevant isoenzyme" semType="phsu, aapp, enzy"/><RxNorm RxCui="6021"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.54.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.54.e.1"/></sentence><sentence biomedicalEntities="3" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55" lineNumber="87" text="Human pharmacokinetic studies with an oral formulation of treprostinil (treprostinil diolamine) indicated that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil increases exposure (both Cmax and AUC) to treprostinil. " type="regular"><entity charOffset="136:178" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.0" text="cytochrome P450 (CYP) 2C8 enzyme inhibitor" type="Drug_Class"><Normalization><mmtx cui="C0014432" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Enzyme Inhibitors" semType="phsu"/><mmtx cui="C0919438" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Enzyme Inhibitor Drugs" semType="phsu"/><RxNorm RxCui="3065"/></Normalization></entity><entity charOffset="179:190" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1" text="gemfibrozil" type="Drug"><Normalization><mmtx cui="C0017245" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><mmtx cui="C0017245" phraseText="that co-administration of the cytochrome P450 (CYP) 2C8 enzyme inhibitor gemfibrozil" preferredWord="Gemfibrozil" semType="phsu, lipd"/><RxNorm RxCui="4719"/></Normalization></entity><entity charOffset="233:245" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.3" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="AUC) to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="191:209|216:220" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.4" text="increases exposure Cmax" type="Increase_Interaction"/><entity charOffset="191:209|225:228" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.6" text="increases exposure AUC" type="Increase_Interaction"/><drugClassMembership drug="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1" drugClass="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.0"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.4"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.3"/></relation></relations></interaction></drugInteraction><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.ddi.2"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.6"><relations><relation type="hasPrecipitant"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.3"/></relation></relations></interaction></drugInteraction><pair ddi="true" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.3" trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.55.e.4" type="Increase_Interaction"/></sentence><sentence biomedicalEntities="3" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56" lineNumber="87" text="Co-administration of the CYP2C8 enzyme inducer rifampin decreases exposure to treprostinil. " type="regular"><entity charOffset="25:46" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.0" text="CYP2C8 enzyme inducer" type="Drug_Class"><Normalization><RxNorm RxCui="687277"/></Normalization></entity><entity charOffset="47:55" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.1" text="rifampin" type="Drug"><Normalization><mmtx cui="C0035608" phraseText="Co-administration of the CYP2C8 enzyme inducer rifampin" preferredWord="Rifampin" semType="orch, antb"/><RxNorm RxCui="9384"/></Normalization></entity><entity charOffset="78:90" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.3" text="treprostinil" type="Drug"><Normalization><mmtx cui="C1145760" phraseText="exposure to treprostinil." preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="56:74" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.4" text="decreases exposure" type="Decrease_Interaction"/><drugClassMembership drug="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.1" drugClass="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.0"/><drugInteraction id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.ddi.1"><interaction trigger="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.4"><relations><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.3"/></relation><relation type="hasObject"><entity id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.56.e.1"/></relation></relations></interaction></drugInteraction></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59" text="Drug interaction studies have been carried out with treprostinil (oral or subcutaneous) co-administered with acetaminophen (4 g/day), warfarin (25 mg/day), and fluconazole (200 mg/day), respectively in healthy volunteers. " type="negative"><entity charOffset="109:122" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.0" text="acetaminophen" type="Biomedical_Entity"><Normalization><mmtx cui="C2917659" phraseText="co-administered with acetaminophen" preferredWord="Acetaminophen [EPC]" semType="phsu"/><RxNorm RxCui="161"/></Normalization></entity><entity charOffset="134:142" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.1" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="52:64" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.2" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="out with treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="160:171" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.3" text="fluconazole" type="Biomedical_Entity"><Normalization><mmtx cui="C0016277" phraseText="fluconazole" preferredWord="Fluconazole" semType="phsu, orch"/><RxNorm RxCui="4450"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.0" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.3"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.59.e.3"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.61" text="Treprostinil does not affect the pharmacokinetics or pharmacodynamics of warfarin. " type="negative"><entity charOffset="73:81" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.61.e.0" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="pharmacodynamics of warfarin." preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="0:12" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.61.e.1" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="Treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.61.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.61.e.0"/></sentence><sentence id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62" text="The pharmacokinetics of R- and S- warfarin and the INR in healthy subjects given a single 25 mg dose of warfarin were unaffected by continuous subcutaneous infusion of treprostinil at an infusion rate of 10 ng/kg/min." type="negative"><entity charOffset="168:180" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.0" text="treprostinil" type="Biomedical_Entity"><Normalization><mmtx cui="C1145760" phraseText="unaffected by continuous subcutaneous infusion of treprostinil" preferredWord="Treprostinil" semType="eico, phsu"/><RxNorm RxCui="343048"/></Normalization></entity><entity charOffset="81:92" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.1" text="a 25" type="Biomedical_Entity"><Normalization><mmtx cui="C0718136" phraseText="a single 25 mg dose of warfarin" preferredWord="A-25" semType="phsu, orch, vita"/><RxNorm RxCui="NA"/></Normalization></entity><entity charOffset="34:42" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.2" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><entity charOffset="104:112" id="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.3" text="warfarin" type="Biomedical_Entity"><Normalization><mmtx cui="C0043031" phraseText="a single 25 mg dose of warfarin" preferredWord="Warfarin" semType="phsu, orch, hops"/><RxNorm RxCui="11289"/></Normalization></entity><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.3" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.0"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.2" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.1"/><pair ddi="false" e1="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.1" e2="Dailymed.cbc31ab1-a80f-4b50-a3b1-39910b0fb609.s.62.e.3"/></sentence><positiveExamples number="8"/><negativeExamples number="49"/></document>